ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Bone Metastases

Bone Metastases

Men with painful bone metastases from prostate cancer may be able to achieve clinically meaningful improvements in pain and quality of life as early as 10 days after undergoing radiotherapy.

Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks.

Bone metastases are common in advanced breast cancer, and may be associated with serious morbidity, including fractures, pain, nerve compression, and hypercalcemia. Through optimum multidisciplinary management and the use of bone-targeted treatments, patients with advanced breast cancer have experienced a major reduction in skeletal complications, less bone pain, and an improved quality of life.

It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.

Analyses from the phase III ALSYMPCA trial showed that treatment with radium-223 resulted in quality-of-life improvements over placebo in patients with castration-resistant prostate cancer and symptomatic bone metastases.

A novel program combining radiation oncology with palliative care in patients with painful bone metastases increased the use of proven treatments while maintaining pain management, decreased palliative radiation use, and decreased hospital length of stay.

The use of bone-seeking radionuclides effectively controlled bone pain in men with prostate cancer metastatic to the bone, according to the results of a systematic review.

Pages

Subscribe to Bone Metastases on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.